Since then, GLP-1 drugs have gone mainstream, often hailed as a medical breakthrough for weight loss
It's not going to be a solution for peptides, Hughes says
Bn cnh , mi sn phm u c hng dn s dng ring, do bn cn c k v tun th ng liu lng trnh gy tng tc thuc
(2020) as stable and being able to maintain their capacity to inhibit DPP4, while non-embedded peptides suffered secondary hydrolysis by proteases in gastrointestinal fluids and lost their inhibitory effects (129)
We are also particularly interested in disproportionate access to these medications by social drivers of health, including treatment disruptions for patients with diabetes and gaps in access to highly effective treatments for overweight and obesity due to lack of insurance coverage (Wright et al., 2023)
Importantly, SCFAs can cross the BBB via monocarboxylate transporters located on endothelial cells and influence BBB integrity by upregulating the expression of tight junction proteins [186] and thereby potentially exert direct effects on microglia
